- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Wockhardt reports PAT at Rs 15 crore in Q3
Mumbai: Pharmaceutical and Biotechnology major, Wockhardt Limited, reported the company's third Quarter Results for Financial Year 2020-21.The Company has reported EBITDA of Rs.56 crore (as compared to Rs.27 crore in the previous quarter i.e Q2FY21) mainly driven by enhanced Revenue and Cost rationalisation. Profit after Tax (PAT) for the Quarter was Rs.15 crore against a marginal profit of...
Mumbai: Pharmaceutical and Biotechnology major, Wockhardt Limited, reported the company's third Quarter Results for Financial Year 2020-21.
| Q3 FY21 | Q2 FY21 | Q3 FY20 | 9M FY21 | 9M FY20 |
Oct - Dec 2020 | Jul - Sep 2020 | Oct - Dec 2019 | Apr - Dec 2020 | Apr - Dec 2019 | |
INR Cr | INR Cr | INR Cr | INR Cr | INR Cr | |
Sales | 764 | 714 | 869 | 2,130 | 2,534 |
EBITDA before R&D* EBITDA % to Sales | 97 12.7% | 72 10.1% | 154 17.7% | 158 7.4% | 373 14.7% |
R&D R&D % to Sales | 42 5.4% | 45 6.3% | 45 5.2% | 124 5.8% | 165 6.5% |
EBITDA* EBITDA Margins % | 56 7.3% | 27 3.8% | 109 12.5% | 34 1.6% | 208 8.2% |
Exceptional Items # |
- |
- |
- |
1,328 |
- |
PBT | 31 | (85) | 16 | 1,094 | (132) |
Profit After Tax PAT Margins % | 15 2.0% | 4 0.5% | 9 1.1% | 779 36.6% | (117) -4.6% |
EPS (Rs) | 1.4 | 0.3 | 0.9 | 70.3 | (10.6) |
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751